City
Epaper

Argentina approves emergency use of Sinopharm vax for kids

By IANS | Updated: October 7, 2021 09:10 IST

Buenos Aires, Oct 7 Argentina has recently approved the emergency use of the Chinese Sinopharm Covid-19 vaccine for ...

Open in App

Buenos Aires, Oct 7 Argentina has recently approved the emergency use of the Chinese Sinopharm Covid-19 vaccine for children aged between three and 11, according to health authorities.

According to an announcement made by Health Minister Carla Vizzotti, here are approximately 6 million children in that age group, Xinhua news agency reported on Thursday.

Vizzotti also noted Argentina plans to complete vaccinating people aged over three years old by the end of this year.

Education officials said they expect the move to help resume in-person learning in Argentina.

Since the onset of the pandemic early last year, Argentina has registered a total of 5,263,219 coronavirus cases and 115,379 deaths.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: ArgentinaXinhuaBuenos AiresBaiCarla vizzottiDistrict data
Open in App

Related Stories

International7.4 Magnitude Earthquake Strikes Chile and Argentina, Tsunami Warning Issued

FootballARG 4-1 BRA, FIFA World Cup 2026 Qualifier: Messi-Less Argentina Thrash Brazil

FootballLionel Messi to Play in India: Will the Argentine 'Magic Man' Visit Kerala for La Albiceleste?

EntertainmentLiam Payne Passes Away: One Direction Singer Dies At 31 After Fall From Balcony In Argentina

InternationalMajor UK Railway Stations Hit by Cyber Attack; Network Rail Suspends Wi-Fi Service

Health Realted Stories

HealthMeghalaya launches health advancement policy

HealthJitendra Singh urges ANRF to help medical colleges boost clinical innovation

HealthStudy finds everyday habits boost mental well-being

HealthSpanking children can impact academic outcomes, impair social-emotional development: Study

HealthMolecular profiling key to reduce radiation for women with endometrial cancer: Study